Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Up 39.6% in April

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 14,100 shares, a growth of 39.6% from the March 31st total of 10,100 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 22,000 shares, the short-interest ratio is presently 0.6 days.

Barinthus Biotherapeutics Price Performance

Barinthus Biotherapeutics stock traded up $0.09 during midday trading on Monday, reaching $2.59. The company’s stock had a trading volume of 4,158 shares, compared to its average volume of 18,873. The firm has a market capitalization of $100.80 million, a PE ratio of -1.35 and a beta of -0.52. The stock’s 50-day simple moving average is $2.69. Barinthus Biotherapeutics has a 52-week low of $1.64 and a 52-week high of $5.10.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings data on Wednesday, March 20th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.10. Equities research analysts predict that Barinthus Biotherapeutics will post -2.6 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BRNS has been the subject of several recent analyst reports. William Blair reiterated an “outperform” rating on shares of Barinthus Biotherapeutics in a research note on Monday, January 8th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Barinthus Biotherapeutics in a research report on Friday, April 19th.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.